This MicroRNA Might Help Detect, Treat Ovarian Cancer

June 26, 2020 6:00 pm

In cell and mouse models, miR-181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.

By Ian Demsky

A microRNA that is normally involved in immune cell differentiation helps to initiate

Read more

Treatment with Lipophilic Statins Shows Lower Mortality Rate for Patients with Epithelial Ovarian Cancer

June 22, 2020 6:00 pm

A study presented at the AACR Virtual Annual Meeting II showed a significant decrease in mortality rate for patients with epithelial ovarian cancer when treated with lipophilic statins, supporting the further evaluation of statins to treat ovarian cancer in randomized Read more

Single-Cell Analysis of Ovarian Cancer Points to Potential Treatment Avenue

June 22, 2020 10:00 am

Inhibiting the JAK/STAT pathway could represent a potential treatment for high-grade serous ovarian cancer, according to a single-cell analysis.

Researchers led by the Broad Institute’s Aviv Regev used single-cell RNA sequencing (scRNA-seq) to analyze about 11,000 cells from ascites from … Read more

Berzosertib: Protein-Targeting Drug Used to Treat Cancer May Have Same Effect on Coronavirus

June 16, 2020 7:00 pm

Scientists have begun using berzosertib, a protein-targeting drug, as an accompaniment to chemotherapy for patients with ovarian cancer. The drug is currently in its second phase of trials with cancer patients and is showing promising results for how it … Read more

FDA Approves Pembrolizumab for TMB-High Tumors

June 16, 2020 3:00 am

The FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden–high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options.Read more

Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer

June 5, 2020 8:00 am

By Audrey Sternberg

The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer.

The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib … Read more

Final Results of KEYNOTE-100 for Patients With Advanced Ovarian Cancer

June 3, 2020 5:00 pm

Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020).

In the interim … Read more

Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer

May 30, 2020 5:00 pm

By Susan Moench, PhD, PA-C

This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.

Early results from a single-arm phase 1b study conducted in … Read more

First Study To Report OS Benefit After Secondary Cytoreductive Surgery in Select Patients With Recurrent Ovarian Cancer

May 29, 2020 5:00 pm

By Susan Moench, PhD, PA-C

According to results of a prospective, randomized clinical trial of selected patients with platinum-sensitive, recurrent ovarian cancer assigned to receive second-line platinum-based chemotherapy preceded by secondary cytoreductive surgery versus not, OS was significantly longer for … Read more

Combined Cediranib and Olaparib Presents Similar Activity to Standard of Care Treatment

May 29, 2020 10:00 am

Combined cediranib and olaparib presents similar activity to standard of care treatment for platinum-sensitive ovarian cancer.

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based … Read more

Immunotherapy With Neoadjuvant Chemotherapy Signals Efficacy in Advanced-Stage Ovarian Cancer

March 19, 2020 11:00 am

By Nichole Tucker

GEN-1 immunotherapy demonstrated dose-dependent efficacy results in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) when treated in combination with the standard of care, according to results from the OVATION 2 … Read more

IMV preps pivotal trials for ovarian cancer T cell therapy

February 26, 2020 11:00 am

IMV says new results from its phase 2 trial of lead drug DPX-Survivac, designed to stimulate a T cell response in ovarian cancer, have set it on course for a registration trial.

The Canadian biotech revealed data from the 22-patient … Read more

Weekly Dose-Dense Chemo Not Recommended in First-Line Epithelial Ovarian Cancer Treatment

December 20, 2019 6:00 pm

By Matthew Fowler

Weekly dose-dense paclitaxel as a frontline treatment for patients with epithelial ovarian cancer was not found to significantly improve progression-free survival (PFS) compared to the standard 3-weekly chemotherapy, according to results from the ICON8 study published in … Read more

Small, Thin Metal Mesh Loaded With T Cells Shrinks Tumors in Ovarian Cancer Models

December 9, 2019 6:00 pm

What if a metal that’s already used to repair broken bones, straighten teeth and keep arteries from clogging could also be used to stop your cancer from spreading?

New findings published Dec. 9 in Nature Biomedical Engineering from scientists at … Read more

Second Surgery for Many Ovarian Cancers Found Ineffective

November 14, 2019 5:00 pm

By Gene Emery

Going back into the operating room for surgery to help a woman whose ovarian cancer has reappeared may not help her live longer – instead, it might shorten her life, according to an international study of 485 … Read more

Genetically Definable Subgroups of Cancers Sensitive to Treatment

October 24, 2019 5:00 pm

Precision oncology aims to use genetic features of a patient’s tumor to tailor anti-cancer therapy. DNA mutations in a drug target have provided a number of therapeutic opportunities; however, there are many cancer types that do not have obvious targetable … Read more

FDA Approves Zejula for Advanced Ovarian Cancer Subset

October 23, 2019 3:30 pm

By Jessica Skarzynski

The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous Read more

Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more

Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC

September 30, 2019 6:00 pm

By Pam Harrison

Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.

Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more